406 related articles for article (PubMed ID: 28487189)
1. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
[TBL] [Abstract][Full Text] [Related]
2. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
3. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
4. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
Allam AN; Hamdallah SI; Abdallah OY
Int J Nanomedicine; 2017; 12():4733-4745. PubMed ID: 28740381
[TBL] [Abstract][Full Text] [Related]
5. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
[TBL] [Abstract][Full Text] [Related]
6. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
7. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
8. Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment.
Mumuni MA; Kenechukwu FC; Ofokansi KC; Attama AA; Díaz DD
Carbohydr Polym; 2020 Feb; 229():115506. PubMed ID: 31826394
[TBL] [Abstract][Full Text] [Related]
9. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
10. Uptake mechanism of furosemide-loaded pegylated nanoparticles by cochlear cell lines.
Youm I; Youan BB
Hear Res; 2013 Oct; 304():7-19. PubMed ID: 23747541
[TBL] [Abstract][Full Text] [Related]
11. Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant.
Mehrabi M; Dounighi NM; Rezayat Sorkhabadi SM; Doroud D; Amani A; Khoobi M; Ajdary S; Pilehvar-Soltanahmadi Y
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):230-240. PubMed ID: 29260901
[TBL] [Abstract][Full Text] [Related]
12. Response Surface Methodology for Statistical Optimization of Chitosan/Alginate Nanoparticles as a Vehicle for Recombinant Human Bone Morphogenetic Protein-2 Delivery.
Zohri M; Akbari Javar H; Gazori T; Khoshayand MR; Aghaee-Bakhtiari SH; Ghahremani MH
Int J Nanomedicine; 2020; 15():8345-8356. PubMed ID: 33154637
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ; Amir M; Pottoo FH; Sarafroz M; Jafar M; Umar K
Int J Biol Macromol; 2019 May; 128():825-838. PubMed ID: 30690115
[TBL] [Abstract][Full Text] [Related]
14. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
15. Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment.
Ahmad N; Al-Subaiec AM; Ahmad R; Sharma S; Alam MA; Ashafaq M; Abdur Rub R; Ahmad FJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):475-490. PubMed ID: 30739499
[TBL] [Abstract][Full Text] [Related]
16. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation.
El-Habashy SE; Allam AN; El-Kamel AH
Int J Nanomedicine; 2016; 11():2369-80. PubMed ID: 27307735
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.
Sharma M; Sharma R; Jain DK; Saraf A
Int J Biol Macromol; 2019 Aug; 135():246-260. PubMed ID: 31128197
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
19. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations.
Mahjub R; Radmehr M; Dorkoosh FA; Ostad SN; Rafiee-Tehrani M
Drug Dev Ind Pharm; 2014 Dec; 40(12):1645-59. PubMed ID: 24093431
[TBL] [Abstract][Full Text] [Related]
20. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate:
Aljaeid BM; El-Say KM; Hosny KM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
